Navigation Links
Vermillion Supports First World Ovarian Cancer Day and Effort to Raise Awareness of the Need for Better Diagnosis and Treatment
Date:5/8/2013

hlighted the deficiencies in the detection and treatment of ovarian cancer, including coverage by the New York Times and NBC Nightly News. According to Dr. Bristow, the director of gynecologic oncology services at UC Irvine Healthcare and principal investigator of the study highlighted in these articles, "If we could just make sure that women get to the people who are trained to take care of them, the impact would be much greater than that of any new chemotherapy drug or biological agent."

Vermillion, which has been dedicated to addressing these deficiencies, has achieved remarkable results with its OVA1® test, the first FDA-cleared test designed to aid in the prediction of malignancy prior to surgery on an ovarian mass. Vermillion developed the OVA1 test together with Johns Hopkins University after nearly a decade of proteomic research. In two published clinical studies, OVA1 demonstrated 96% sensitivity across a broad range of ovarian malignancies and detected over 90% of all early stage ovarian cancers. The studies also reported a 95%-98% negative predictive value, a critical feature for minimizing the likelihood that a non-oncology surgeon discovers ovarian cancer during surgery. The powerful performance of OVA1 helps to ensure that women with ovarian cancer are treated by a gynecologic oncologist, which is a critical determinant of survival.

Since receiving FDA clearance in 2009, Vermillion has worked to increase insurance coverage for the test, as well as greater use by physicians.

"Despite the strong progress we've made, with more than 42,000 test performed to-date, the adoption rate of OVA1 has been far too slow," noted McLain "We are hopeful that a special day dedicated to building ovarian cancer awareness can hel
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vermillion Sets First Quarter 2013 Conference Call for Wednesday, May 15, 2013
2. Vermillion Appoints Thomas McLain as President and Chief Executive Officer
3. Vermillion Reports Fourth Quarter and Full Year 2012 Results
4. Vermillion to Discuss Preliminary Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013, at 4:30 p.m. ET
5. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
6. Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
7. Delaware Court of Chancery Dismisses Vermillion Dissident Shareholder Suit with Prejudice
8. Vermillion Reports Third Quarter 2012 Results
9. Vermillion Sets Third Quarter 2012 Conference Call for Monday, November 12, 2012 at 4:30 p.m. ET
10. Vermillion to Present at the 2012 Gateway Conference on September 6
11. Vermillion Reports Second Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... and PITTSBURGH , Aug. ... ) today announced that its shareholders have approved ... PRGO ; TASE) and the related issuance ... an extraordinary general meeting of shareholders held today. ... cast at the extraordinary general meeting. In addition, ...
(Date:8/28/2015)... -- The report "Eubiotics Market by Type (Probiotics, Prebiotics, Organic ... & by Region ( North America , ... Rest of the World) - Global Trends and Forecast to ... valued at USD 4.62 Billion in 2014 and is projected ... of 7.4% from 2015 to 2020. Browse ...
(Date:8/28/2015)... Massachusetts and LONDON , August ... approach seamlessly connects ... continuum improving outcomes and the ...  (NYSE: PHG AEX: PHIA) today announced its presence at  ... latest cardiology solutions, including Heart Model A.I. , EchoNavigator and ...
Breaking Medicine Technology:Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that ... received preferred Tier 2 formulary status with all ... benefits manager, Prescription Solutions ® .  The AARP ... MedicareComplete from Secure Horizons, provide prescription drug access ...
... Omeros Corporation (NASDAQ: OMER ) ... its product candidates from its PharmacoSurgery™ platform – ... lens replacement surgery – into Phase 3 clinical ... added to standard irrigation solutions and delivered intra-operatively ...
Cached Medicine Technology:Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 2Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 3Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 4Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 5Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 6Omeros Announces Clinical Development Programs for OMS103HP and OMS302 2Omeros Announces Clinical Development Programs for OMS103HP and OMS302 3Omeros Announces Clinical Development Programs for OMS103HP and OMS302 4Omeros Announces Clinical Development Programs for OMS103HP and OMS302 5
(Date:8/29/2015)... ... ... Brands like Toppik , Eau Thermale Avene and Bliss are now available on ... was required to qualify for free standard shipping,” said Jennifer Ramirez, the public relations ... of the item’s selling price.” , With competitive pricing in the e-commerce market for ...
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops ... seconds of unique footage that users can shrink and stretch in the Final Cut ... Users can customize color, brightness, scale, speed, range, and flare attributes with intuitive controls ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain have ... soft tissue manipulation. Platelet rich plasma injections also have mixed results. Building ... treatment outcomes. This localized treatment seems to address the symptoms and does ...
(Date:8/29/2015)... Houston, TX (PRWEB) , ... August 29, 2015 ... ... settlement allows the company to freely market and sell Arterosil and Arterosil HP, ... Daniels Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a ... Memorial Hospital recently transitioned management companies to partner with Wound Care Advantage (WCA) ... outpatient wound center. , Transitioning wound care management providers can be a ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... by leading food management company ... 6 Pura Vida Coffee and leading food,service management ... the organizations announced at Pura Vida,s tenth,anniversary celebration in ... certified coffee, tea and,hot chocolate as official Fair Trade ...
... Small-Molecule Drugs for ... Spinal ... PTC Therapeutics, Inc.,(PTC), a biopharmaceutical company focused on the ... today announced an expanded,research collaboration with the Spinal Muscular ...
... Dec. 6 OPKO Health, Inc. (Amex: OPK ... lead,compound for the treatment of wet age-related macular degeneration ... promising drugs entering Phase III,clinical trials during the third ... issue of The Ones to Watch report issued by ...
... Dec. 6 MyLongLife.com -- China is rushing ... the most ancient medical,systems on Earth embraces the ... MyLongLife.com., This dramatic thrust is being driven ... http://www.worldhealth.net/ ) reports,MyLongLife., It culminated ...
... HAYWARD, Calif., Dec. 6 Arete Therapeutics Inc., ... the treatment of cardiovascular, inflammatory and,metabolic diseases, today ... board of directors., "We are very pleased ... as his,strategic and operational insights will be of ...
... France, December 6 Essilor,has strengthened its prescription ... stakes in Sinclair Optical Services and United,Optical, two ... also acquired Premier Optics, Inc., Gold Optical Enterprises, ... Based in Gloucester, England, Sinclair Optical serves the ...
Cached Medicine News:Health News:Pura Vida Coffee and Compass Group Announce Strategic Partnership 2Health News:Pura Vida Coffee and Compass Group Announce Strategic Partnership 3Health News:PTC Therapeutics Announces Additional $1.6 Million Grant from the Spinal Muscular Atrophy Foundation 2Health News:PTC Therapeutics Announces Additional $1.6 Million Grant from the Spinal Muscular Atrophy Foundation 3Health News:OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials 2Health News:OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials 3Health News:OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials 4Health News:China's Anti-Aging Revolution 2Health News:China's Anti-Aging Revolution 3Health News:Arete Therapeutics Appoints Donald Santel to Board of Directors 2Health News:Essilor Acquires Prescription Laboratories in the United Kingdom and the United States 2
10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
10 L, Bulk Recommended for 5 & 10 L pipettes. Ideal for pipetting into long, narrow tubes or deep well plates....
This extended 10 ul combats contamination by keeping your pipettor out of 1.5 ul and 2.0 ul tubes. Utilizes MicroPoint design and 2 ul reference mark....
... The MonoPrep LBP Processor is a primary ... specimen collection, accessioning, processing, sampling, and slide ... data management. The MonoPrep LBP Processor produces ... from a broad range of cytology specimen ...
Medicine Products: